Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs

http://ift.tt/2prw6qS

Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials

Future Oncology Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2qp51Up
via IFTTT

Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials

Future Oncology Ahead of Print.


http://ift.tt/2qp51Up

Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials

Future Oncology Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2qp51Up
via IFTTT

Intravoxel incoherent motion DWI of the pancreatic adenocarcinomas: monoexponential and biexponential apparent diffusion parameters and histopathological correlations

Abstract

Background

To investigate the associations between the diffusion parameters obtained from multiple-b-values diffusion weighted imaging (DWI) of pancreatic ductal adenocarcinoma (PDAC) and the aggressiveness and local stage prediction, and assess the values of the quantitative parameters for the discrimination of tumors from healthy pancreas.

Methods

Fifty-one patients with surgical pathology-proven PDAC (size, 35 ± 12 mm) and fifty-seven healthy volunteers were enrolled. Diffusion parameters including monoexponential apparent diffusion coefficient (ADC_b and ADC_total) and biexponential intravoxel incoherent motion (IVIM) parameters (ADC_slow, ADC_fast and f) based on 9 b-values (0 to 1000s/mm²) DWI were calculated for the lesions and the healthy pancreas. These parameters were compared by grades of differentiation, lymph node status, tumor stage and location. The diagnostic performances were calculated and compared by using the receiver operating characteristic curves (ROC) analyses.

Results

There was no statistically significant difference in ADC_b, ADC_total, ADC_slow, ADC_fast or f between PDAC stage T1/T2 and stage T3/T4 or moderately differentiated versus poorly differentiated PDAC (p = 0.060-0.941). In addition, no significant differences were observed for the quantitative parameters between tumors located in the pancreatic head versus other pancreatic regions (p = 0.203-0.954) or between tumors with and without metastatic peri-pancreatic lymph nodes (p = 0.313-0.917). ADC_25-600, ADC₁₀₀₀, ADC_total and ADC_fast were significantly lower for PDAC compared the healthy pancreas (all p < 0.05). ROC analyses showed the area under curve for ADC₂₀ was the largest (0.911) to distinguish PDAC from normal pancreas (cut-off value, 5.58 × 10⁻³mm²/s) and had the highest combined sensitivity (89.5%) and specificity (82.4%).

Conclusions

Multiple-b-values DWI derived monoexponential and biexponential parameters of PDAC do not exhibit significance dependence on tumor grade or tumor characteristics. ADC₂₀ provided the best accuracy for differentiating PDAC from healthy pancreas in the study.

http://ift.tt/2qfKzsz

Intravoxel incoherent motion DWI of the pancreatic adenocarcinomas: monoexponential and biexponential apparent diffusion parameters and histopathological correlations

Abstract

Background

To investigate the associations between the diffusion parameters obtained from multiple-b-values diffusion weighted imaging (DWI) of pancreatic ductal adenocarcinoma (PDAC) and the aggressiveness and local stage prediction, and assess the values of the quantitative parameters for the discrimination of tumors from healthy pancreas.

Methods

Fifty-one patients with surgical pathology-proven PDAC (size, 35 ± 12 mm) and fifty-seven healthy volunteers were enrolled. Diffusion parameters including monoexponential apparent diffusion coefficient (ADC_b and ADC_total) and biexponential intravoxel incoherent motion (IVIM) parameters (ADC_slow, ADC_fast and f) based on 9 b-values (0 to 1000s/mm²) DWI were calculated for the lesions and the healthy pancreas. These parameters were compared by grades of differentiation, lymph node status, tumor stage and location. The diagnostic performances were calculated and compared by using the receiver operating characteristic curves (ROC) analyses.

Results

There was no statistically significant difference in ADC_b, ADC_total, ADC_slow, ADC_fast or f between PDAC stage T1/T2 and stage T3/T4 or moderately differentiated versus poorly differentiated PDAC (p = 0.060-0.941). In addition, no significant differences were observed for the quantitative parameters between tumors located in the pancreatic head versus other pancreatic regions (p = 0.203-0.954) or between tumors with and without metastatic peri-pancreatic lymph nodes (p = 0.313-0.917). ADC_25-600, ADC₁₀₀₀, ADC_total and ADC_fast were significantly lower for PDAC compared the healthy pancreas (all p < 0.05). ROC analyses showed the area under curve for ADC₂₀ was the largest (0.911) to distinguish PDAC from normal pancreas (cut-off value, 5.58 × 10⁻³mm²/s) and had the highest combined sensitivity (89.5%) and specificity (82.4%).

Conclusions

Multiple-b-values DWI derived monoexponential and biexponential parameters of PDAC do not exhibit significance dependence on tumor grade or tumor characteristics. ADC₂₀ provided the best accuracy for differentiating PDAC from healthy pancreas in the study.

from Cancer via ola Kala on Inoreader http://ift.tt/2qfKzsz
via IFTTT

Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: A Japanese multicenter pancreatic NEN-G3 study

Purpose: <p>Patients with Pancreatic neuroendocrine neoplasm grade-3 (PanNEN-G3) show variable responses to platinum-based chemotherapy. Recent studies indicated that PanNEN-G3 includes well-differentiated neuroendocrine tumor with G3 (NET-G3). Here, we examined the clinicopathological and molecular features of PanNEN-G3 and assessed the responsiveness to chemotherapy and survival.</p> Experimental Design: 100 patients with PanNEN-G3 were collected from 31 institutions, and after central review characteristics of each histological subtype (NET-G3 versus pancreatic neuroendocrine carcinoma (NEC-G3)) were analyzed, including clinical, radiological, and molecular features. Factors that correlate with response to chemotherapy and survival were assessed. <br /><br />Results: <p>70 patients analyzed included 21 NETs-G3 (30%) and 49 NECs-G3 (70%). NET-G3 showed lower Ki67-LI (median 28.5%), no abnormal Rb expression (0%), and no mutated KRAS (0%), whereas NEC-G3 showed higher Ki67-LI (median 80.0%), Rb loss (54.5%), and KRAS mutations (48.7%). Chemotherapy response rate (RR), platinum-based chemotherapy RR, and prognosis were significantly different between NET-G3 and NEC-G3. Chemotherapeutic outcomes were worse in NET-G3 (P<0.001). When we stratified PanNEN-G3 with Rb and KRAS, PanNENs-G3 with Rb loss and those with mutated KRAS showed significantly higher RRs to platinum-based chemotherapy than those without (Rb loss, 80% versus normal Rb, 24%, p=0.006; mutated KRAS, 77% versus wild-type, 23%, p=0.023). Rb was a predictive marker for response to platinum-based chemotherapy even in NEC-G3 (P=0.035).</p> Conclusions: <p>NET-G3 and NEC-G3 showed distinct clinicopathological characteristics. Notably, NET-G3 does not respond to platinum-based chemotherapy. Rb and KRAS are promising predictors of response to platinum-based chemotherapy for PanNEN-G3, and Rb for NEC-G3.

http://ift.tt/2qoTHHW